Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 88 Lung Neoplasms 53 Carcinoma, Hepatocellular 43 Breast Neoplasms 33 Small Cell Lung Carcinoma 29 Squamous Cell Carcinoma of Head and Neck 23 Cholangiocarcinoma 22 Urinary Bladder Neoplasms 21 Colorectal Neoplasms 21 Pancreatic Neoplasms 20 Ovarian Neoplasms 17 Triple Negative Breast Neoplasms 16 Biliary Tract Neoplasms 16 Neoplasm Metastasis 13 Head and Neck Neoplasms 12 Neoplasms 11 Carcinoma, Renal Cell 11 Liver Neoplasms 9 Endometrial Neoplasms 9 Carcinoma, Transitional Cell 9 Uterine Cervical Neoplasms 7 Esophageal Neoplasms 7 Carcinoma, Squamous Cell 7 Adenocarcinoma Of Esophagus 7 Recurrence 6 Prostatic Neoplasms 6 Mesothelioma, Malignant 6 Melanoma 6 Gallbladder Neoplasms 6 Fallopian Tube Neoplasms 6

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × durvalumab × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡